About YU

News

YU Research Team Develops Next-Generation Cancer Immunostimulant That Boosts Immunity to Fight Cancer Cells N

No.232345662
  • Writer PR team
  • Date : 2026.11.02 13:43
  • Publication Date : 2026.10.20
  • Views : 2249

YU and YU Medical Center Jointly Develop Cancer Immunostimulant That Enhances the Body’s Own Immune Response

Overcomes Limitations of Existing Immunostimulants in Cancer Treatment … Stronger Antitumor Effects at the Same Dose

“Combination Therapy with Existing Anticancer Drugs Could Reduce Side Effects and Improve Cancer Patients’ Quality of Life”

Research Published in Biomaterials, a Prestigious International Journal in the Biomaterials Field; Patent Application Filed

[October 20, 2026]

<From left: Dr. JEONG Ji-yoon; Master’s graduate YUN In-seop; Research Professor LEE Geun-woo of Michigan State University College of Human Medicine (formerly a professor at YU College of Medicine); and Professor HONG Cheol-am of YU Department of Chemistry.>


A joint research team led by Professor HONG Cheol-am of the Department of Chemistry at Yeungnam University (YU; President CHOI Oe-chool) and Research Professor LEE Geun-woo of Michigan State University College of Human Medicine, formerly a professor at YU College of Medicine, has developed a next-generation cancer immunostimulant designed to activate the human immune system and maximize its ability to eliminate cancer cells.


This research presents an immuno-oncology technology that treats cancer by enhancing patients’ own immune responses. Unlike conventional anticancer drugs, which directly attack cancer cells, this approach strengthens the function of immune cells in the body. It is attracting attention as a potential alternative that could substantially reduce the toxicity and side effects associated with conventional cancer treatment.


The team focused on CpG oligodeoxynucleotides (CpG ODNs), immunostimulants used to enhance the effectiveness of infectious disease vaccines. Although these agents are highly effective at activating immune cells, they are rapidly degraded in the body, making them difficult to use as cancer immunostimulants capable of targeting cancer cells distributed throughout the body. 


To overcome this limitation, the researchers applied pH-sensitive i-motif DNA technology. Using this approach, they developed CpG i-dimer, a novel nanostructure formed by linking two CpG ODN molecules. Compared with conventional CpG ODNs, CpG i-dimer remains more stable in the body and is designed to enter macrophages--the immune cells responsible for key immune functions--more readily. Notably, once inside endosomes, mildly acidic compartments within macrophages, CpG i-dimer separates into two individual CpG ODN molecules through a distinctive mechanism. This process increases the efficiency of CpG ODN-mediated immune activation within macrophages, enabling a stronger antitumor immune response at the same administered dose.


In animal experiments involving mice with induced malignant melanoma (skin cancer), tumors in mice treated with CpG i-dimer were approximately 2.7 times smaller than those in mice treated with conventional CpG ODNs at the same dose. The treated mice also survived approximately 1.5 times longer than those in the conventional CpG ODN group. These findings demonstrated the strong antitumor efficacy of CpG i-dimer and its biocompatibility, with no observed toxicity or side effects, at the animal-testing stage.

<Mechanism of Antitumor Immune Activation by CpG i-dimer in Mice with Induced Tumors>


Professor HONG Cheol-am, who led the research, explained, “The significance of this study lies in overcoming the limitations of existing immunostimulants in cancer treatment by designing a novel DNA nanostructure without complex chemical modifications. In particular, the study presents a new strategy for enhancing immune activation within macrophages by harnessing the structural properties of pH-responsive DNA, making it valuable from both technological and academic perspectives.” He added, “Going forward, we plan to enhance treatment efficacy through combination therapy with existing anticancer drugs and expand the application of this technology to various cancer types. Our ultimate goal is to commercialize it as a next-generation cancer immunostimulant following systematic toxicity testing and clinical trials.”


KIM Sam-su, YU Vice President for Industry-Academia-Research Affairs, said, “This research is the result of YU’s ongoing efforts to support interdisciplinary and convergent research between its College of Medicine and the university’s other academic departments. We will continue to actively support innovative collaborative research that transcends disciplinary boundaries and consistently produces world-class research outcomes.”



The findings were recently published online in Biomaterials, a prestigious international journal in the biomaterials field, with an Impact Factor (IF) of 13.6, placing it in the top 3.6% of journals in its category. The article is scheduled for formal publication in March 2027. The paper is titled “Acidic pH-responsive and dissociative dimeric CpG oligodeoxynucleotides for enhanced cancer immunotherapy.” Dr. JEONG Ji-yoon and Master’s graduate YUN In-seop, both graduates of YU’s Department of Chemistry graduate program, served as co-first authors. Research Professor LEE Geun-woo of Michigan State University College of Human Medicine was a co-author, and Professor HONG Cheol-am of YU’s Department of Chemistry served as the corresponding author. The team has filed a patent application covering the core technology and will continue its research with the goal of future commercialization.